These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 8045754

  • 41. Improving adherence with deferoxamine regimens for patients receiving chronic transfusion therapy.
    Treadwell MJ, Weissman L.
    Semin Hematol; 2001 Jan; 38(1 Suppl 1):77-84. PubMed ID: 11206966
    [Abstract] [Full Text] [Related]

  • 42. Deferoxamine in thalassemia major.
    Cazzola M, Locatelli F, De Stefano P.
    N Engl J Med; 1995 Jan 26; 332(4):271-2; author reply 272-3. PubMed ID: 7808503
    [No Abstract] [Full Text] [Related]

  • 43. The management of the improved prognosis in thalassemia major.
    Modell B.
    Birth Defects Orig Artic Ser; 1982 Jan 26; 18(7):329-37. PubMed ID: 6819016
    [No Abstract] [Full Text] [Related]

  • 44. [Role and therapeutic use of deferoxamine in iron overload due to thalassemia (author's transl)].
    Lévy G, Bachelot C, Joannard A, Bost M.
    Arch Fr Pediatr; 1980 May 26; 37(5):299-303. PubMed ID: 7469704
    [Abstract] [Full Text] [Related]

  • 45. Deferoxamine in children with recurrent neuroblastoma.
    Blatt J.
    Anticancer Res; 1994 May 26; 14(5B):2109-12. PubMed ID: 7840508
    [Abstract] [Full Text] [Related]

  • 46. [Evaluation of iron balance in homozygous beta-thalassemia subjects treated with desferrioxamine administered subcutaneously].
    Ferrara M, Galdo Capotorti M, Ponte G, Esposito L.
    Pediatria (Napoli); 1983 May 26; 91(4):371-7. PubMed ID: 6545400
    [No Abstract] [Full Text] [Related]

  • 47. Iron excretion in thalassemia children treated with deferoxamin methansulfonat: intravenous drip compared to the subcutaneous routes.
    Hathirat P, Areekul S, Isarangkura P, Chantachum Y.
    J Med Assoc Thai; 1989 Jan 26; 72 Suppl 1():121-4. PubMed ID: 2732632
    [Abstract] [Full Text] [Related]

  • 48. Evaluation of the incidence of sensorineural hearing loss in beta-thalassemia major patients under regular chelation therapy with desferrioxamine.
    Karimi M, Asadi-Pooya AA, Khademi B, Asadi-Pooya K, Yarmohammadi H.
    Acta Haematol; 2002 Jan 26; 108(2):79-83. PubMed ID: 12187025
    [Abstract] [Full Text] [Related]

  • 49. [Experience with desferrioxamine treatment by intravenous administration, in thalassemia].
    Barcellona R, Masseria R, Palmigiano C, Amato GM.
    Minerva Pediatr; 1979 May 31; 31(10):809-12. PubMed ID: 470859
    [No Abstract] [Full Text] [Related]

  • 50. Sensorimotor neurotoxicity associated with high-dose deferoxamine treatment.
    Levine JE, Cohen A, MacQueen M, Martin M, Giardina PJ.
    J Pediatr Hematol Oncol; 1997 May 31; 19(2):139-41. PubMed ID: 9149744
    [Abstract] [Full Text] [Related]

  • 51. Mineral balance (iron, aluminum, copper, zinc) after high-dose intravenous Desferal in a child with hemoglobin Hammersmith and Turner's syndrome.
    Hyman CB, Gonick HC, Neufeld N, Agness CL.
    Am J Pediatr Hematol Oncol; 1989 May 31; 11(4):450-5. PubMed ID: 2618982
    [Abstract] [Full Text] [Related]

  • 52. [German multicenter thalassemia study. Concept and initial results].
    Kohne E, Stahnke K, Kulozik AE, Kleihauer E.
    Klin Padiatr; 1992 May 31; 204(4):258-63. PubMed ID: 1518262
    [Abstract] [Full Text] [Related]

  • 53. Sensorineural hearing loss in children with thalassemia major in Northern Greece.
    Kontzoglou G, Koussi A, Tsatra J, Noussios G, Vital V, Sagarakis G, Athanassiou M.
    Int J Pediatr Otorhinolaryngol; 1996 May 31; 35(3):223-30. PubMed ID: 8762595
    [Abstract] [Full Text] [Related]

  • 54. Regression of cardiac insufficiency after ambulatory intravenous deferoxamine in thalassemia major.
    Wacker P, Halperin DS, Balmer-Ruedin D, Oberhansli I, Wyss M.
    Chest; 1993 Apr 31; 103(4):1276-8. PubMed ID: 8131484
    [Abstract] [Full Text] [Related]

  • 55. Combined subcutaneous and high-dose intravenous deferoxamine therapy of thalassemia.
    Hyman CB, Agness CL, Rodriguez-Funes R, Zednikova M.
    Ann N Y Acad Sci; 1985 Apr 31; 445():293-303. PubMed ID: 3860133
    [Abstract] [Full Text] [Related]

  • 56. Dose-dependent pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine.
    Rego EM, Neto EB, Simões BP, Zago MA.
    Am J Hematol; 1998 Aug 31; 58(4):340-1. PubMed ID: 9692403
    [No Abstract] [Full Text] [Related]

  • 57. Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy.
    Orton RB, de Veber LL, Sulh HM.
    Can J Ophthalmol; 1985 Jun 31; 20(4):153-6. PubMed ID: 4052864
    [Abstract] [Full Text] [Related]

  • 58. Iron balance and the management of iron overload in beta-thalassemia intermedia.
    Pippard MJ, Weatherall DJ.
    Birth Defects Orig Artic Ser; 1988 Jun 31; 23(5B):29-33. PubMed ID: 3390555
    [No Abstract] [Full Text] [Related]

  • 59. Oral isobutyramide reduces transfusion requirements in some patients with homozygous beta-thalassemia.
    Reich S, Bührer C, Henze G, Ohlendorf D, Mesche M, Sinha P, Kage A, Müller C, Vetter B, Kulozik AE.
    Blood; 2000 Nov 15; 96(10):3357-63. PubMed ID: 11071627
    [Abstract] [Full Text] [Related]

  • 60. Cultural preferences and limited public resources influence the spectrum of thalassemia in Egypt.
    Adly AA, Ebeid FS.
    J Pediatr Hematol Oncol; 2015 May 15; 37(4):281-4. PubMed ID: 25811748
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.